News

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...
Stocktwits on MSN19h
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy
Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...